Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Lipodystrophy news


From To
The mirror has two faces - a personal account of using facial filler for lipoatrophy

In the end, for me the few small lumps, the cost of treatment, and the pain were all a small price to pay for what it has ultimately done for my self-esteem. I feel better about myself overall, because I look healthier.

28 September 2012
Positively Aware
Theratechnologies sinks on HIV drug setback

The Committee for Medicinal Products for Human Use in Europe cited potential concerns for long-term users and a lack of data on cardiovascular risks as the reason for its unfavorable view of the drug, Theratechnologies said in a statement.

22 June 2012
Why it's time to say goodbye to stavudine...everywhere

Concerns about a proposed comparative trial of 40mg and 20mg (low-dose) stavudine in South Africa.

16 April 2012
South African Journal of HIV Medicine
Face fillers and dental work—caution needed

Reconstructive surgery to deal with the loss of subcutaneous fat in the face involved injection of facial fillers. One product used was polyalkylimide gel (PAIG, Bio-Alcamid). However, reports began to emerge from Western Europe of inflammation and infections in both HIV-negative and HIV-positive people with Bio-Alcamid implants. 

25 January 2012
Theratechnologies to discontinue COPD clinical program and focus on lipodystrophy

The Company will now focus its efforts on tesamorelin's significant potential for the treatment of excess abdominal fat in HIV patients with lipodystrophy. Currently, applications for this indication are under review with regulatory agencies in Europe, Argentina, Brazil, Canada, Israel and Mexico.

08 December 2011
Theratechnologies press release
Body Satisfaction Increased With Fat Gains in Prezista Study

Although treatment experienced HIV-positive men and women had slightly greater gains in trunk fat after switching to a new regimen containing Prezista (darunavir), they also reported increased satisfaction with their bodies.

17 June 2011
Theratechnologies seeks European marketing for lipodystrophy drug Tesamorelin

Theratechnologies Inc. says it has applied to sell its lead drug tesamorelin in Europe. The drug is a treatment for excess abdominal fat in adult HIV-infected patients with lipodystrophy.

07 June 2011
Stock House
What Lies Ahead: An Activist's View of Promising HIV Treatment Research

After attending the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) in Boston, Mass., and following different areas of research, I decided to write down a list of advancements that really thrill and energize me as an educator and research advocate.

31 March 2011
The Body
European regulator restricts use of d4T (stavudine, Zerit)

In view of the side effects seen with the medicine, the CHMP recommended that the marketing authorisation for Zerit should be renewed with restrictions. The Committee recommended that, for both adults and children, it should be used for as short a time as possible and only when there are no appropriate alternatives.

18 February 2011
European Medicines Agency
HIV Lipo Drug Egrifta Now Available; Financial Assistance Programs Open

Egrifta (tesamorelin), the lipodystrophy treatment approved by the U.S. Food and Drug Administration (FDA) late last year, is now officially available to people living with HIV and their health care providers, according to EMD Serono.

27 January 2011
← Prev12Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.